Despite their similar nomenclature, Neurofibromatosis type 1 (NF1) and “Neurofibromatosis type 2” are discrete and clinically distinguishable entities. The name of “neurofibromatosis type 2” has been changed to NF2-related schwannomatosis, to reflect the fact that neurofibromas do not occur in this syndrome and therefore the name “Neurofibromatosis” is factually incorrect. Furthermore, multiple schwannomas, a hallmark feature of NF2, can also occur in patients with mutations in genes including SMARCB1 and LZTR1, all exhibiting overlapping clinical features. Current understanding suggests that schwannomatosis (SWN) encompasses a range of clinical presentations consisting of clearly defined, separate subtypes which share a common phenotype of schwannomas. Recognizing these newly emerging subtypes, the International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC) proposed a revised nomenclature for NF2 and related disorders in 2022. This review article focuses on this critical update in diagnostic terminology, highlighting the key gene-related SWN subtypes relevant to neuroradiologists. By emphasizing molecular testing alongside clinical features, the revised system facilitates a more precise diagnosis, potentially paving the way for personalized treatment strategies. Additionally, the flexible structure accommodates future discoveries of genes associated with SWN.
EvansDSainioMBaserM. Neurofibromatosis type 2. J Med Genet2000; 37(12): 897–904. DOI: 10.1136/jmg.37.12.897.
2.
RouleauGAMerelPLutchmanM, et al.Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature1993; 363(6429): 515–521. DOI: 10.1038/363515a0.
3.
PiotrowskiAXieJLiuYF, et al.Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet2014; 46(2): 182–187. DOI: 10.1038/ng.2855.
4.
HulsebosTJMPlompASWoltermanRA, et al.Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet2007; 80(4): 805–810. DOI: 10.1086/513207.
5.
MoyhuddinABaserMEWatsonC, et al.Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet2003; 40(6): 459–463. DOI: 10.1136/jmg.40.6.459.
6.
EvansDGRRamsdenRTShentonA, et al.Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet2007; 44(7): 424–428. DOI: 10.1136/jmg.2006.047753.
7.
EvansDGHartleyCLSmithPT, et al.Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genet Med2020; 22(1): 53–59. DOI: 10.1038/s41436-019-0598-7.
8.
PlotkinSRMessiaenLLegiusE, et al.Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med2022; 24(9): 1967–1977. DOI: 10.1016/j.gim.2022.05.007.
9.
SestiniRBacciCProvenzanoA, et al.Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat2008; 29(2): 227–231. DOI: 10.1002/humu.20679.
10.
LegiusEMessiaenLWolkensteinP, et al.Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med2021; 23(8): 1506–1513. DOI: 10.1038/s41436-021-01170-5.
11.
MehtaGUFeldmanMJWangH, et al.Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation. J Neurosurg2016; 125(6): 1469–1471. DOI: 10.3171/2015.11.JNS151766.
12.
GrippKWBakerLKandulaV, et al.Constitutional LZTR1 mutation presenting with a unilateral vestibular schwannoma in a teenager. Clin Genet2017; 92(5): 540–543. DOI: 10.1111/cge.13013.
13.
MerkerVLEsparzaSSmithMJ, et al.Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncol2012; 17(10): 1317–1322. DOI: 10.1634/theoncologist.2012-0162.
14.
EvansDGR. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis2009; 4: 16. DOI: 10.1186/1750-1172-4-16.
15.
GhalavandMAAsghariAFarhadiM, et al.The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell Int2023; 23: 99. DOI: 10.1186/s12935-023-02940-8.
16.
OstlerBKilleenDEReischJ, et al.Patient demographics influencing vestibular schwannoma size and initial management plans. World Neurosurg2020; 136: e440–e446. DOI: 10.1016/j.wneu.2020.01.019.
17.
StivarosSMStemmer-RachamimovAOAlstonR, et al.Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet2015; 52(8): 557–562. DOI: 10.1136/jmedgenet-2015-103050.
18.
DewanRPemovAKimHJ, et al.Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol2015; 17(4): 566–573. DOI: 10.1093/neuonc/nou317.
19.
ChoiJWLeeJYPhiJH, et al.Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2. J Neurosurg Pediatr2014; 13(6): 650–657. DOI: 10.3171/2014.3.PEDS13455.
20.
CastellanosEPlanaACarratoC, et al.Early genetic diagnosis of neurofibromatosis type 2 from skin plaque plexiform schwannomas in childhood. JAMA Dermatol2018; 154(3): 341–346. DOI: 10.1001/jamadermatol.2017.5464.
EvansDGBirchJMRamsdenRT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child1999; 81(6): 496–499. DOI: 10.1136/adc.81.6.496.
23.
GugelIGrimmFTeuberC, et al.Presenting symptoms in children with neurofibromatosis type 2. Childs Nerv Syst2020; 36(10): 2463–2470. DOI: 10.1007/s00381-020-04729-w.
24.
Stemmer-RachamimovAOHorganMATaratutoAL, et al.Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. J Neuropathol Exp Neurol1997; 56(5): 485–489. DOI: 10.1097/00005072-199705000-00004.
25.
RubinsteinLJ. The malformative central nervous system lesions in the central and peripheral forms of neurofibromatosis. A neuropathological study of 22 cases. Ann N Y Acad Sci1986; 486: 14–29. DOI: 10.1111/j.1749-6632.1986.tb48058.x.
26.
HallidayDEmmanouilBPretoriusP, et al.Genetic Severity Score predicts clinical phenotype in NF2. J Med Genet2017; 54(10): 657–664. DOI: 10.1136/jmedgenet-2017-104519.
27.
DhamijaRPlotkinSGomesA, et al.LZTR1- and SMARCB1-related schwannomatosis. In: AdamMPFeldmanJMirzaaGM, et al. (eds). GeneReviews®. University of Washington, Seattle, 1993. https://www.ncbi.nlm.nih.gov/books/NBK487394/ (Accessed 9 June 2024).
28.
LiPZhaoFZhangJ, et al.Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution. J Neurosurg Spine2016; 24(1): 145–154. DOI: 10.3171/2015.3.SPINE141145.
29.
GonzalvoAFowlerACookRJ, et al.Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up. Clinical article. J Neurosurg2011; 114(3): 756–762. DOI: 10.3171/2010.8.JNS091900.
30.
HartJGardnerJMEdgarM, et al.Epithelioid schwannomas: an analysis of 58 cases including atypical variants. Am J Surg Pathol2016; 40(5): 704–713. DOI: 10.1097/PAS.0000000000000589.
31.
JoVYFletcherCDM. SMARCB1/INI1 loss in epithelioid schwannoma: a clinicopathologic and immunohistochemical study of 65 cases. Am J Surg Pathol2017; 41(8): 1013–1022. DOI: 10.1097/PAS.0000000000000849.
32.
OstrowKLBergnerALBlakeleyJ, et al.Creation of an international registry to support discovery in schwannomatosis. Am J Med Genet2017; 173(2): 407–413. DOI: 10.1002/ajmg.a.38024.
33.
RousseauGNoguchiTBourdonV, et al.SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. BMC Neurol2011; 11: 9. DOI: 10.1186/1471-2377-11-9.
34.
TsurusakiYOkamotoNOhashiH, et al.Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. Nat Genet2012; 44(4): 376–378. DOI: 10.1038/ng.2219.
35.
van den MunckhofPChristiaansIKenterSB, et al.Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics2012; 13(1): 1–7. DOI: 10.1007/s10048-011-0300-y.
36.
EellooJASmithMJBowersNL, et al.Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant. Fam Cancer2019; 18(4): 445–449. DOI: 10.1007/s10689-019-00138-4.
37.
SmithMJBowersNLBulmanM, et al.Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology2017; 88(1): 87–92. DOI: 10.1212/WNL.0000000000003418.
38.
PathmanabanONSadlerKVKamaly-AslID, et al.Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults. JAMA Neurol2017; 74(9): 1123–1129. DOI: 10.1001/jamaneurol.2017.1406.
39.
JordanJSmithMSeijoM, et al.LZTR1 mutations associated with greater pain among patients with schwannomatosis (P6.142). Neurology2018; 90(15_supplement): P6–142. DOI: 10.1212/WNL.90.15_supplement.P6.142.
40.
FarschtschiSMautnerVPhamM, et al.Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis. Ann Neurol2016; 80(4): 625–628. DOI: 10.1002/ana.24753.
41.
LekMKarczewskiKJMinikelEV, et al.Analysis of protein-coding genetic variation in 60,706 humans. Nature2016; 536(7616): 285–291. DOI: 10.1038/nature19057.
42.
YamamotoGLAguenaMGosM, et al.Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet2015; 52(6): 413–421. DOI: 10.1136/jmedgenet-2015-103018.
43.
JohnstonJJvan der SmagtJJRosenfeldJA, et al.Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. Genet Med2018; 20(10): 1175–1185. DOI: 10.1038/gim.2017.249.
44.
UmekiINiihoriTAbeT, et al.Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes. Hum Genet2019; 138(1): 21–35. DOI: 10.1007/s00439-018-1951-7.
